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Cancer progression is accompanied by widespread transcriptional changes and metabolic
alterations. While it is widely accepted that the origin of cancer can be traced to
the mutations that accumulate over time, relatively recent evidence favors a similarly
fundamental role for alterations in the epigenome during tumorigenesis. Changes in
epigenetics that arise from post-translational modifications of histones and DNA are
exploited by cancer cells to upregulate and/or downregulate the expression levels of
oncogenes and tumor suppressors, respectively. Although the mechanisms behind these
modifications, in particular how they lead to gene silencing and activation, are still being
understood, most of the enzymatic machinery of epigenetics require metabolites as
substrates or cofactors. As a result, their activities can be influenced by the metabolic
state of the cell. The purpose of this review is to give an overview of cancer epigenetics
and metabolism and provide examples of where they converge.
Keywords: Warburg effect, metabolic signaling, NAD metabolism, α-ketoglutarate and cancer, TCA cycle, histone
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INTRODUCTION
Epigenetics is defined as heritable changes in gene expression
without alterations in the underlying genetic material (Morgan
et al., 2005). Modifications include DNA methylation and cova-
lent post-translational modifications of histones such as acetyla-
tion, methylation, phosphorylation, ubiquitination, phosphory-
lation, and crotonylation (Sharma et al., 2010; Tan et al., 2011).
Since every cell in the body has the same genetic code, epigenetic
regulation of gene expression plays a large role in determining
cellular identity. Failure of proper maintenance of cellular epige-
netic status can, thus, result in loss of tissue identity or aberrant
signaling pathways that lead to developmental defects or dis-
ease states such as diabetes and cancer (Esteller, 2008; Slomko
et al., 2012). It is now well accepted that cancer initiation and
progression are driven by a series of genetic and epigenetic alter-
ations that cause either activation of oncogenes or inactivation
of tumor suppressor genes. Much of the recent excitement in the
field of cancer epigenetics lies in the reversible nature of epigenetic
alterations; unlike genomic mutations, these changes can theo-
retically be reversed by epigenetic therapy. Recently, four drugs
that target the epigenetic machinery have been approved by the
FDA for cancer treatment and have demonstrated prolonged sur-
vival and lower toxicity than conventional chemotherapy (Kelly
et al., 2010; Baylin and Jones, 2011). Despite intensive research
and remarkable advances in our understanding of epigenetics, the
mechanisms and regulators that trigger pathological epigenetic
reprogramming in cancer remains poorly understood.
Another emerging hallmark of cancer is themetabolic rewiring
within cancer cells (Hanahan and Weinberg, 2011). More than
80 years ago, the biochemist Otto Warburg observed that cancer
cells consume abnormally large amounts of glucose and produce
high amounts of lactate even in the presence of oxygen (Warburg,
1956). Research over the past few years has reinforced this obser-
vation and furthermore revealed altered metabolism of lipids,
amino acids, and nucleotides in cancer cells (Vander Heiden
et al., 2009; Koppenol et al., 2011; Ward and Thompson, 2012).
Interestingly, emerging evidence has suggested that epigenetics
and metabolism might be tightly linked in cancer development
(Teperino et al., 2010; Katada et al., 2012; Lu and Thompson,
2012). Epigenetic alterations in cancer can affect metabolic status
directly by regulating the expression of metabolic enzymes, thus
contributing to the metabolic reprograming in cancer (Goel et al.,
2003; Chen et al., 2011; Wolf et al., 2011). Reciprocally, metabolic
reprograming in cancer can affect epigenetic status which in turn
alters the gene expression of oncogenes and/or tumor suppres-
sors or chromatin structures (Hitchler and Domann, 2009; Lu
and Thompson, 2012; Wellen and Thompson, 2012). In fact, vir-
tually all epigenetic enzymes rely on metabolites as co-factors or
substrates (Locasale and Cantley, 2011). In this review, we will
focus on the interaction between epigenetics and metabolism. We
will first discuss the interaction of epigenetics and metabolism-
related to cancer development. Then, we will highlight recent
work showing how alterations in cancer metabolism can shift
the concentrations of co-factors or substrates and thus influence
epigenetic gene regulation and chromatin structure.
EPIGENETIC REPROGRAMING IN CANCER
DNA METHYLATION
In mammalian DNA, the fifth position carbon of cytosine within
cytosine guanine (CpG) dinucleotides can become methylated
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(Esteller, 2008). There are dense regions of these CpG dinu-
cleotides throughout the genome. These dense regions are called
“CpG islands” and defined by a GC percentage and an observed-
to-expected CpG ratio (Takai and Jones, 2002). CpG islands
are estimated to occupy 50–70% of human gene promoters and
under most conditions, methylation of CpG islands at gene pro-
moters is associated with gene silencing (Ulrey et al., 2005).
DNA methylation is catalyzed by a family of DNA methyltrans-
ferases (DNMTs), which transfers a methyl group, donated by
S-adenosylmethionine (SAM), to the fifth position carbon of
cytosine. There are three catalytically active DNMTs in the mam-
malian genome: DNMT1, DNMT3A, and DNMT3B (Bestor,
2000). DNMT1 is primarily known as a maintenance DNMT
having a greater specificity for hemi-methylated DNA and is
important for maintaining the DNA methylation patterns dur-
ing replication. DNMT3A and 3B are considered primarily de
novo methyltransferases. While the enzymes that carry out DNA
methylation have been relatively well characterized, much less has
been understood regarding how DNA undergoes demethylation.
Two models, one involving a passive mechanism and the other
an active mechanism, have been proposed to explain observations
(Ooi and Bestor, 2008). After multiple rounds of DNA replication
and cell division, methylation patterns can simply fail to be pre-
served in the genomes of the daughter cells if DNMT1 is persis-
tently inhibited encompassing the passive demethylation process.
This is believed to occur during multiple stages of development
and cellular differentiation (Morgan et al., 2005). Alternatively,
recent work has suggested that the physical removal of the 5′
methyl group from 5-methylcytosine (5meC) is also occurring
(Kangaspeska et al., 2008; Metivier et al., 2008). More than one
enzyme is thought to participate in this process, which involves
a series of enzymatic steps at the heart of which lies the ten-
eleven translocation (TET) proteins (Bhutani et al., 2011). The
TET proteins (TETs 1, 2, and 3) utilize oxygen and α-ketoglutarate
(α-KG) to catalyze multiple rounds of oxidation reactions, con-
verting 5meC to 5-hydroxymethylcytosine (5hmC) and then to
5-formylcytosine (5fC) and finally to 5-carboxylcytosine (5caC)
(Tahiliani et al., 2009; Ito et al., 2010, 2011; He et al., 2011). 5hmC,
5fC, and 5caC have all been identified as oxidative byproducts of
cytosine upon exposure to hydroxyl radicals. As such, DNA repair
enzymes are involved in the removal and subsequent restoration
of unmodified cytosine (Wu and Zhang, 2010). These obser-
vations suggest a previously unappreciated role of DNA repair
enzymes as the final step in reversing an important transcriptional
regulatory phenomenon.
The cancer epigenome is marked by genome-wide hypomethy-
lation and aberrant site-specific CpG island promoter hyperme-
thylation (Sandoval and Esteller, 2012). While the underlying
mechanisms that initiate these changes are still not clear, recent
studies indicate that some changes occur in early-stage tumors
and may contribute to cancer initiation (Esteller, 2008). Global
DNA hypomethylation takes place at various genomic sequences
such as repetitive elements, retrotransposons, introns, and gene
deserts. Hypomethylation at these regions leads to increased
genomic instability resulting in chromosomal rearrangement
(Rodriguez et al., 2006). In addition, DNA hypomethylation can
cause the activation of growth-promoting genes, such as R-RAS
in gastric cancer, S-100 in colon cancer (Wilson et al., 2007)
and melanoma-associated antigen (MAGE) in melanoma, and
a loss of imprinting (LOI) in various tumors (Rainier et al.,
1993; Sharma et al., 2010). More often studied is the aberrant
promoter hypermethylation, which in contrast to hypomethyla-
tion, contributes to tumorigenesis by silencing tumor suppressors
such as retinoblastoma (RB), cyclin-dependent kinase inhibitor
2A (CDKN2A, also called p16), mutL homolog-1 (MLH1),
von-Hippel-Lindau tumor suppressor (VHL), and breast cancer-
associated-1 (BRCA1) (Jones and Baylin, 2002, 2007). The repro-
gramming of epigenetics in cancer has been recently supported by
the finding of somatic mutations in DNMT3A in acute myeloid
leukemia (AML) (Ley et al., 2010). Furthermore, homozygous
null mutations and chromosomal deletion involving the TET2
locus have been identified in various myeloid malignances, indi-
cating that the impairment of the active DNA demethylation
process might contribute to cancer development (Delhommeau
et al., 2009; Ko et al., 2010).
HISTONE MODIFICATIONS (ACETYLATION AND METHYLATION)
Covalent modifications of lysine or arginine residues of histones
are an integral part of epigenetics. The epigenetic status of his-
tones have been demonstrated to influence transcription, DNA
repair, and replication (Esteller, 2008). While there are a num-
ber of different types of post-translational modifications, we will
focus on two of the most well-researched histone modifications
in cancer in this review—lysine acetylation and methylation.
Histone acetylation is a dynamic process that is regulated through
the antagonistic activities of two large families of enzymes—the
histone acetyltransferases (HATs) and the histone deacetylases
(HDACs) (Shahbazian and Grunstein, 2007). The HATs and
HDACs are also known as lysine acetyltranferserases (KATs) or
lysine deacetylases (KDACs), respectively, since it is now appre-
ciated that they acetylate- or deacetylate-numerous non-histone
substrates (Kurdistani, 2007). HATs are grouped into three main
subfamilies: GCN5-related N-acetyltransferase (GNAT), MYST
histone acetyltransferase, and p300/CBP. While functionally dis-
tinct, each subfamily shares the common enzymatic activity of
transferring the acetyl groups from acetyl-CoA to the lysine
residues. Conversely, HDACs remove acetyl groups from lysine
residues on histones. HDACs are divided into four groups (classes
I–IV) (Zhang and Dent, 2005). Eleven of HDACs belong to class
I, II, or IV and are dependent on Zn2+ (Haberland et al., 2009)
The other seven members, known as the Sirtuins, belong to class
III and require nicotinamide adenine dinucleotide (NAD+) as
an essential cofactor. Generally, histone acetylation is associated
with transcriptional activation whereas histone deacetylation is
correlated with gene repression and silencing (Lane and Chabner,
2009).
Compared to lysine acetylation, lysine methylation has
the additional complexity of undergoing multiple rounds
of modification, generating three distinct states of lysine
(monomethylated, dimethylated, and trimethylated lysine)
(Varier and Timmers, 2011). Furthermore, the outcome of
histone methylation can lead to transcriptional activation or
repression depending on the position of the lysine that is
modified (Vakoc et al., 2005; Berger, 2007; Bernstein et al.,
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2007). For instance, trimethylation of lysine (K) 4 on histone H3
(H3K4me3) is usually associated with transcriptional activation
whereas H3K9me3 or H3K27me3 is strongly correlated with
heterochromatin-mediated gene silencing. These modifica-
tions are carried out by histone methyltransferases (HMTs).
HMTs constitute three classes of enzymes: SET domain lysine
methyltransferases, non-SET domain lysine methyltransferases
and arginine methyltransferases. Like DNMTs, all HMTs use
SAM as a coenzyme to transfer methyl groups to lysine or
arginine residues of substrate proteins. Lysine methyltransferases
have remarkable target specificity, and they usually modify
one single lysine on a single histone (Shi et al., 2004). Until
recently, histone methylation was considered a terminal event
(Takamura and Nomura, 1988). This view had changed with
the discovery of lysine-specific demethylase 1 (LSD1) and JmjC
(Jumonji C) domain demethylase (JHDM), collectively known as
histone demethylases (HDM) (also known as lysine demethylase
(KDMs) (Teperino et al., 2010). LSD1 is a highly conserved
protein, homologous to other flavine adenine dinucleotide
(FAD)-dependent oxidases, composed of two subdomains:
a FAD-binding and a substrate-binding domain. LSD1 catalyzes
demethylation of mono- and di-methylated H3K9 or K4, leading
to context-dependent transcriptional activation or repression
(Shi et al., 2004, 2005). JHDMs have a mechanism different
from that of LSD1. Like the TET family discussed earlier, they
belong to the oxygenase family and demethylate histones in
an α-KG and Fe2+-dependent manner (Klose et al., 2006a,b;
Tsukada et al., 2006).
As with DNA methylation, changes in histone modifications
are also common in cancer (Kurdistani, 2007). One of the most
prominent characteristics is global loss of acetylation of H4K16Ac
(Fraga et al., 2005). Such loss of histone acetylation, which is
mediated by HDACs, results in gene silencing. HDACs, such as
HDAC1, HDAC2, HDAC6 and Sirtuins are often found overex-
pressed in various types of cancer (Halkidou et al., 2004; Song
et al., 2005; Bolden et al., 2006; Saunders and Verdin, 2007)
and thus have become a target for epigenetic therapy (Lane
and Chabner, 2009). HATs which maintain histone acetylation
levels are also altered in cancer. For example, aberrant forma-
tion of fusion proteins through chromosomal translocations of
HATs such as E1A-binding protein p300 (EP300), nuclear recep-
tor coactivator-2 (NCOA2), MYST3 [histone acetyltransferase
(monocytic leukemia) 3] and MYST4 have been identified in
hematological cancers (Yang, 2004). In addition to changes in
histone acetylation, cancer cells also exhibit widespread changes
in histone methylation patterns. Alterations in H3K9 and H3K27
methylation are correlated with aberrant gene silencing in many
types of cancer (Nguyen et al., 2002; Valk-Lingbeek et al., 2004).
The changes of histone methylation in cancer can be par-
tially explained by anomalous expression or activity of HMTs
and HDMs, due to chromosomal translocation, amplification,
deletion, overexpression or silencing. For example, enhancer of
zeste homolog 2 (EZH2), which encodes the H3K27 HMT, is
overexpressed in solid tumors such as breast, skin, prostate,
lung, and colon cancer (Bracken and Helin, 2009). Chromosomal
translocation of myeloid/lymphoid or mixed lineage leukemia
(MLL), which encodes the most thoroughly studied H3K4 HMT,
leads to aberrant expression of various homeotic (hox) genes in
leukemic progression (Krivtsov and Armstrong, 2007; Sharma
et al., 2010). HDMs such as LSD1 and JHDM are also reported
to be deregulated in various cancer types (Shi, 2007; Rodriguez-
Paredes and Esteller, 2011; Varier and Timmers, 2011). The com-
binations of alterations of both the HMTs and HDMs in cancer
are thought to contribute to changes in the epigenetic landscape
of cancer.
METABOLIC REPROGRAMMING IN CANCER
Altered metabolism is often observed in cancer (Vander Heiden
et al., 2009; Locasale and Cantley, 2011; Vander Heiden et al.,
2011). This metabolic rewiring enables tumor cells to continu-
ously survive and proliferate even in tumor microenvironments
in which certain nutrients are limiting (Gatenby and Gillies,
2004). Normal cells mostly rely on mitochondrial oxidative phos-
phorylation to generate energy from glucose. In contrast, cancer
cells prefer to metabolize glucose in a larger part by glycolysis,
resulting in increased glucose consumption and lactate produc-
tion even in the presence of ample oxygen (Vander Heiden et al.,
2009). OttoWarburg first observed this phenomenon in the 1920s
(Warburg, 1956). His observation, known as the Warburg effect
or aerobic glycolysis, has become the basis of 18FDG-PET imag-
ing, a common technology to detect and observe many tumors in
current clinical practice (Hsu and Sabatini, 2008).
Importantly, growing evidence indicates that almost all onco-
genes and tumor suppressors are closely involved in these
metabolic reprogramming in cancer (Yun et al., 2009; Ward
and Thompson, 2012). Furthermore, metabolic enzymes such
as succinate dehydrogenase (SDH), fumarate hydratase (FH),
isocitrate dehydrogenases 1/2 (IDH1/2) and phosphoglycerate
dehydrogenase (PHGDH) have been reported to be genetically
altered in various tumors (Baysal et al., 2000; Tomlinson et al.,
2002; Parsons et al., 2008; Locasale et al., 2011; Mullen and
Deberardinis, 2012). Together these findings indicate that the
metabolic switches are not just byproducts of cancer develop-
ment, but major contributors to it.
METABOLIC REGULATION OF EPIGENETICS IN CANCER
The epigenetic enzymes that we discussed in the previous section
require substrates or cofactors that are intermediate metabolites
of cell metabolism. Theoretically, if the levels of these metabolites
are elevated beyond their normal range, promiscuous activation
may occur. Conversely, cancer cells may experience the depletion
of metabolites needed for post-translational modifications of his-
tones or DNAmethylation (Katada et al., 2012). In this section we
will discuss how the perturbation of certainmetabolites in cancers
may influence epigenetic reprograming in cancer in a case by case
basis (summary in Table 1 and Figure 1).
SAM (S-ADENOSYL-L-METHIONINE)
As we discussed previously, SAM is the methyl donor for reactions
catalyzed by both DNMTs and HMTs. In mammalian cells,
SAM is generated through the addition of ATP to methion-
ine by methionine adenosyltransferase (MAT). In completing
the methyl transfer reaction, a byproduct, S-adenosyl homo-
cysteine (SAH) is a potent inhibitor of DNMTs and HMTs
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Table 1 | Link between metabolism and Epigenetics through metabolic co-factors.
Metabolic co-factors Enzymes that use the co-factor Epigenetic function
S-adenosyl-L-methionine (SAM) DNA methyltransferase (DNMTs) DNA methylation
Histone methyltransferases (HMTs) Methylation of histone or non-histone proteins
Acetyl coenzyme A (acetyl-CoA) Histone acetyltransferases (HATs) Acetylation of histone or non-histone proteins
Nicotinamide adenine dinucleotide (NAD+) Sirtuins Deacetylation of histone or non-histone proteins
Flavin adenine dinucelotide (FAD) Lysine specific demthylase 1 (LSD1) Demethylation of histone or non-histone proteins
α-Ketoglutarate (α-KG) Ten-eleven translocation (TETs) DNA demethylation
JmiC histone demethylase (JHDMs) Demehtylation of Histone or non-histone proteins
FIGURE 1 | Interactions between metabolism and epigenetics.
Metabolites that are used as substrates and cofactors for reactions that
coordinate epigenetic status (red colors) are centered in this diagram,
with the corresponding enzymes that utilize them shown with their
chemical reactions. Abbreviation used in this figure: AceCS1, Acetyl-CoA
synthetase 1; ACL, ATP-citrate lysase; Ac-CoA, Acetyl-CoA; Acy-protein,
Acetylated-protein; Ado, Adenosine; α-KG, α-ketoglutarate; CoA,
Co-enzyme; DNMT, DNA methyltransferase; ETC, Electron transport chain;
FAD, Flavine adenine dinucleotide; FADH2, Flavin adenine dinucleotide
dihydride; GSH, Glutathione; HAT, Histone acetyltransferases; Hcy,
Homocystein; HDM, Histone demethylases; 2-HG, 2-hydroxyglutarate;
HMT, Histon methyltransferase; IDH1/2, Isocitrate dehydrogenases 1/2;
JMDH, JmjC (Jumonji C) domain demethylase; LSD1, Lysine-specific
demethylase 1; MAT, Methionine adenosyltransferase; Mut, mutation;
NAD+, Nicotinamide adenine dinucleotide; NADH, Nicotinamide adenine
dinucleotide hydride; SAH, S-adenosylhomocysteine; SAHH, SAH
hydrolase; SAM, S-adenosylmethionine; TCA, Tricarboxylic acid; TET2,
Ten-eleven translocation 2.
(Grillo and Colombatto, 2008). This inhibition is relieved once
SAH is hydrolyzed to adenosine and homocysteine by SAH
hydrolase (SAHH). Homocysteine has multiple fates (Grillo and
Colombatto, 2008). It can be remethylated to restore methionine
either by methionine synthase using N5-methyl tetrahydrofo-
late (THF) as methyl donor, or betaine homocysteine methyl-
transferase (BHMT) using choline-derived betaine as the methyl
donor. Alternatively, homocysteine can enter the transsulfura-
tion pathway forming cysteine, a precursor for glutathione (GSH)
synthesis. These processes can be dictated in part by the given
cellular requirements. Rapid cell proliferation, as seen in cancers,
often results in the overproduction of reactive oxygen species
(ROS) (Trachootham et al., 2009). Under these conditions, levels
of GSH, a major cellular redox buffer, are elevated to minimize
the deleterious effects of ROS. In this pro-oxidant state, homo-
cysteine is diverted away from the methionine recycling pathway
into the transsulfuration pathway to produce cysteine, which is
a precursor and a rate limiting factor in GSH synthesis (Beutler,
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1989). Conceivably, a tradeoff may be at play where there needs a
decision to commit its limited resources to the collective methy-
lation of histones or DNA or to the maintenance of its redox
state. Consistent with this notion, when GSH is acutely depleted,
genome-wide DNA hypomethylation follows (Lertratanangkoon
et al., 1996, 1997). As discussed, cancer epigenomes are often
marked by genome-wide DNA hypomethylation. Thus, some
cancers may be exploiting a higher level of ROS for the purpose of
reducing the production of SAM thereby dropping the activities
of DNMTs and HMTs.
Recently, PHGDH, the first enzyme in the serine biosynthetic
pathway, was shown to be genetically amplified in melanoma and
breast cancer (Locasale et al., 2011; Possemato et al., 2011). The
gene amplification was found to associate with higher levels of
flux into serine and glycine metabolism. Since serine donates car-
bon into the folate pool, its flux can control the intracellular levels
of SAM by contributing its one carbon unit to the SAM through
folate pools (Mullarky et al., 2011), it is plausible that PHGDH
amplification might affect the methylation status of DNA and/or
histones regulating the gene expression in cancer cells.
ACETYL-COA (ACETYL COENZYME A)
Acetyl-CoA is the acetyl-group donor for the acetylation of his-
tones and other proteins. The intracellular acetyl-CoA levels have
been observed to have more than a 10-fold variation (4–70μM)
depending on metabolic conditions and nutrient availability
(Takamura and Nomura, 1988; Cai et al., 2011). Since the Km
of most HATs falls within that range, the activities of HATs are
affected by fluctuations of intracellular acetyl-CoA pools. This
suggests an intriguing role for acetyl-CoA as a link between cell
metabolism and gene expression. Such a link was demonstrated
in yeast cells where the loss of the two acetyl-CoA synthetase
enzymes ACS1 and ACS2 showed dramatically reduced levels of
histone acetylation and synthetic lethality resulted from deletion
of the HAT, Gcn5p (Takahashi et al., 2006). Bulk histone acety-
lation was also shown as a response to abundant glucose that
increased production of acetyl-CoA in yeast (Friis et al., 2009).
In mammals, two enzymes, ATP-citrate lysase (ACL) and acetyl-
CoA synthetase 1 (AceCS1), are responsible for generating the
nuclear and cytosolic pools of acetyl-CoA, which can then be
used for either protein acetylation or lipogenesis. Acetyl-CoA is
typically generated in the tricarboxylic acid (TCA) cycle from
glucose-derived pyruvate via pyruvate dehydrogenase (PDH) in
themitochondrial matrix. The excess production of acetyl-CoA in
the mitochondria of proliferating cells or tumor cells results in the
export of its derivative citrate to the cytosol where it is converted
back to acetyl-CoA by ACL. Interestingly, Wellen et al. recently
demonstrated that ACL can serve as a molecular link between cell
metabolism and histone acetylation in response to growth factor
stimulation (Wellen et al., 2009). Global acetylation of histones
and expression of a selective subset of genes are downregulated
in conditions where ACL activity is disturbed. These results from
yeast and humans indicate that global and gene-specific control
of transcription can be intertwined with the metabolic status
of cells via acetyl-CoA. In future work, it would be interesting
to investigate whether there is a causal relationship between the
availability of acetyl-CoA and the global loss of acetylation of
H4K16Ac which is a prevalent characteristic in many cancers (Shi
et al., 2004).
NAD+ (NICOTINAMIDE ADENINE DINUCLEOTIDE)
NAD+ serves as a coenzyme in metabolic redox reactions, a
biosynthetic precursor for several cell signaling molecules, and
a cofactor for enzymes such as sirtuins (NAD+-dependent class
III of HDACs) and poly(ADP-ribose)polymerase (Ying, 2008).
The deacetylation activity of sirtuins consumes NAD+ as a
cofactor and produces a deacetylated protein, nicotinamide, and
the novel compound 2′-O-acetyl-ADP-ribose (Yang and Sauve,
2006). Since NAD+ is an essential cofactor for sirtuin activity,
changes in levels of NAD+ or the NAD+/NADH ratio caused by
metabolic status, are thought to regulate the activity of sirtuins
(Lin et al., 2000; Anderson et al., 2003; Hekimi and Guarente,
2003). The link between sirtuins and metabolic status was first
suggested by the findings that Sir2 in yeast is required for life
span extension resulting from caloric restriction (Howitz et al.,
2003; Sinclair, 2005). It is known that Sir2 activity is stimulated
in nutrient deprived conditions where the ratio of NAD+/NADH
increases. In mammals, sirtuins are key regulators of stress
responses and metabolism, possibly working as a stress buffer
likely through sensing changes in levels of intracellular NAD+
(Martinez-Pastor and Mostoslavsky, 2012). Among seven mem-
bers of the mammalian sirtuin family, SIRT1 and SIRT6 are
localized in the nucleus and possess deacetylase activities. The
most well-studied sirtuin, SIRT1 deacetylates multiple transcrip-
tion coactivators such as forkhead box, class O (FOXO), p53,
peroxisome proliferator-activated receptor gamma, coactivator
1α (PGC1-α) as well as histones (H1, H3, and H4) (Saunders and
Verdin, 2007). Several sirtuins are localized to other organelles;
for example, SIRT3, SIRT4, and SIRT5 are localized to mitochon-
dria. During development, changing the NAD+/NADH ratio
of muscle cells can alter the activity of sirtuins, thus affecting
chromosome structure and gene expression (Fulco et al., 2003;
Backesjo et al., 2006). The role of sirtuins in cancer is complex
and multifaceted with evidence that sirtuins act as both onco-
genes and tumor suppressors. For instance, some sirtuins, such
as SIRT2 and SIRT6 appear to function as tumor suppressors,
but others, such as SIRT1, are suggested to have a dual role
(Bosch-Presegue and Vaquero, 2011). It is tempting to specu-
late that the increased glucose uptake and high rates of glycolysis
(the Warburg effect) in cancer may influence in part sirtuins’
activity by altering the ratio of NAD+/NADH in tumor cells.
Through glycolysis, there is a net reduction NAD+ to NADH,
thus decreasing NAD+/NADH ratio and leading to downregu-
lation of the overall sirtuin activity. Reduced sirtuin activity by
alterations in the NAD+/NADH ratio in cancer cells may result
in histone hyperacetylation and decondensed chromatin struc-
ture that leads to the stimulation of gene expression (Hitchler and
Domann, 2009). Further investigations are needed to understand
these associations among the levels of NAD+, activity of sirtuins,
and histone acetylation in cancer.
FAD (FLAVIN ADENINE DINUCLEOTIDE)
FAD is a redox coenzyme existing in two different redox states
similar to NAD+: oxidized form, FAD and reduced form, FADH2.
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The FADH2 produced in the TCA cycle, loses two electrons being
oxidized back to FAD through the electron transport chain (ETC)
to produce ATP by oxidative phosphorylation. In addition to its
function as a redox coenzyme, FAD is an important cofactor for
the demethylation of histones by the first identified HDM, LSD1
(also known as KDM1). LSD1 is a FAD-dependent monoamine
oxidase which specifically removes methyl groups frommono- or
dimethylated H3K4 or H3K9 through the reduction of FAD to
FADH2 and the release of formaldehyde as a byproduct (Lu and
Thompson, 2012). This can reprogram the chromatin structure
and result in context-dependent activation or repression of tran-
scription (Teperino et al., 2010). As recycling of FAD requires con-
verting oxygen to hydrogen peroxide (H2O2), cellular redox status
may affect the cellular FAD levels and thus LSD1 activity (Lu
and Thompson, 2012). Oxidoreductase enzymes that use FAD as
a cofactor are called flavoproteins. Interestingly, many flavopro-
teins are metabolic enzymes. One example is the enzyme complex
SDH (complex II) that oxidizes succinate to fumarate in the
TCA cycle, thereby reducing FAD to FADH2. Other well-known
flavoproteins include acyl-CoA dehydrogenase, α-ketoglutarate
dehydrogenase (α-KGDH), and a component of the PDH com-
plex (Teperino et al., 2010). The majority of known flavoproteins
are located in the mitochondria or cytosol, whereas LSD1 is
one of a few flavoproteins located in the nucleus (Hino et al.,
2012). Another nuclear flavoprotein is apoptosis-inducing factor
(AIF) that originally localizes to the mitochondrial inner mem-
brane and then translocate to the nucleus upon on oxidative
stress or proapoptotic stimuli (Modjtahedi et al., 2006), indicat-
ing that AIF might transfer FAD pools from the mitochondria
to the nucleus (Pospisilik et al., 2007; Hino et al., 2012). If
so, changed activities of metabolism-related flavoproteins in the
mitochondria might also influence the activity of LSD1 through
competition for the cofactor, FAD suggesting the potential link
between epigenetics and metabolism in cancer. Future analysis
of histone demethylation by LSD1 and the cellular availability of
FAD in cancer will be required to test this conceivable hypothesis.
α-KG (α-KETOGLUTARATE)
α-KG is a key metabolite in the TCA cycle that can be produced
from glucose-derived isocitrate via an interconversion reaction
catalyzed by isocitrate dehydrogenase (IDH) and it can also
be produced by anaplerotic reactions such as transamination
of glutamate or through glutamate dehydrogenase using gluta-
mate as a substrate (Lu and Thompson, 2012). In addition to
its roles in many metabolic pathways in the cytosol and mito-
chondria, α-KG can also enter the nucleus and be used as a
substrate for α-KG/Fe2+-dependent dioxygenases such as TET
and JHDM that modify epigenetic marks (Teperino et al., 2010).
TET2 DNA hydroxylase converts 5meC to 5hmC at CpG dinu-
cleotides using α-KG, oxygen and Fe2+ as cofactors and releases
succinate and formaldehyde as byproducts. A product, 5hmC can
then be an intermediate in either passive (replication-dependent)
or active (TET-dependent) DNA methylation through pathways
that are currently under active investigation (Tahiliani et al., 2009;
He et al., 2011). α-KG is also a cofactor for another dioxyge-
nase enzyme, JHDM that demethylate mono- di- and tri- lysine
residues of histones. Recent discoveries showed that mutations in
the cytosolic IDH1 and mitochondrial IDH2 resulted in a mod-
ified activity of IDH1/2 producing 2-hydroxyglutarate (2-HG)
from α-KG (Dang et al., 2009; Ward et al., 2010). Since 2-HG is
structurally similar to α-KG, it is reasonable to hypothesize that
2-HG can competitively inhibit α-KG-dependent enzymes such
as TET and JHDM, thereby affecting epigenetic regulation.
2-HG (2-HYDROXYGLUTARATE)
The recent discovery of somatic mutations in the metabolic
enzymes, IDH1 and IDH2 in glioblastomas has provided strong
evidence for a beneficial role of altered metabolism in cancer
(Balss et al., 2008; Parsons et al., 2008; Yan et al., 2009). IDH1
and IDH2 are NADP-dependent enzymes that interconvert isoc-
itrate to α-KG in the cytosol and mitochondria, respectively,
as briefly discussed in the previous section. Mutations in these
enzymes have been identified in up to 80% of low-grade gliomas
(Yan et al., 2009), 30% of AML (Mardis et al., 2009; Ward
et al., 2010) and subsets of chondrosarcomas and lymphomas
(Amary et al., 2011a; Cairns et al., 2012). Other solid tumors also
acquire somatic mutations in IDH1/2 (The Cancer Genome Atlas
Network, 2012). Strikingly, the mutations are single amino acid
substitutions at an arginine residue in the active site of the enzyme
(e.g., R132 for IDH1 and R172 in IDH2 in gliomas or R140
for IDH2 in AML). The mutations appear functionally equiv-
alent between the IDH1 and IDH2 enzymes, and all recorded
mutations were found to be heterozygous, retaining one copy of
the wild-type IDH enzyme. These characteristics strongly sug-
gested that the mutations confer a gain-of-function property to
the enzyme. Indeed, recent studies have shown that mutations
of IDH1 and IDH2 lead to a new enzyme activity—catalyzing
the conversion of α-KG to produce 2-HG (Dang et al., 2009).
In IDH1-mutated gliomas, 2-HG accumulates to concentrations
of approximately 5–35mM which is 100-fold higher than that in
gliomas without these mutations (Dang et al., 2009). 2-HG was
also found to accumulate to these levels in IDH1/2 mutated AML
(Gross et al., 2010; Ward et al., 2010; Andersson et al., 2011)
and enchondroma (Amary et al., 2011b). α-KG and 2-HG are
similar in structure, and recent studies have shown that 2-HG
serves as a competitive inhibitor of α-KG dependent dioxygenase
enzymes. More than 60 enzymes utilize α-KG as a cofactor, and
at high concentrations, 2-HG outcompetes α-KG for binding to
several classes of histone demethylases such as TET2 and JHDM
(Chowdhury et al., 2011). High intracellular levels of 2-HG in
IDH1/2 mutant tumors are likely sufficient for potent enzymatic
inhibition and suggest a possible mechanism by which IDH1/2
mutations contribute to tumorigenesis (Chowdhury et al., 2011).
The biological relevance of TET inhibition by 2-HG has strong
genetic evidence: gain of function mutations of IDH1/2 and loss
of function of TET2 mutations were found to be mutually exclu-
sive in a large AML cohort (Figueroa et al., 2010). Furthermore,
TET2 mutant AML samples displayed an overlapping DNA
hypermethylation signatures with samples having IDH1/2 muta-
tions, and shRNA knockdown of TET2 phenocopied the
effect of IDH mutant overexpression on blocking hematopoi-
etic cell differentiation (Figueroa et al., 2010). Moreover,
expression of mutant IDH in cells successfully prevented
increases of 5hmC induced by TET2 (Figueroa et al., 2010).
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In addition, recent study showed that conditional IDH1
(R132H)-knock-in AML mice developed dysfunctional bone
marrow niche and had hypermethylated histones and DNA sim-
ilar to those observed in human IDH- or IDH2-mutant AML
(Sasaki et al., 2012). All together, these studies strongly imply
that a potential link between IDH1/2 mutations and increased
DNA methylation which could be a result of the 2-HG inhibi-
tion of TET activity. In a subset of gliomas, IDH mutations are
also found to be linked with DNA hypermethylation although
no mutations in the TET family members have been reported so
far (Noushmehr et al., 2010; Turcan et al., 2012). Interestingly,
glioma samples with IDH mutations showed higher levels of
H3K9me3 and H3K27me3 which might potentially explain why
2-HG can inhibit the activity of α-KG-dependent JHDMs, which
demethylate histones (Lu et al., 2012). In vitro studies showed that
2-HG could competitively inhibit several JHDMs (Chowdhury
et al., 2011; Xu et al., 2011). Further investigations of muta-
tion studies in α-KG-dependent dioxygenase enzymes including
JHDMs will be needed to genetically link IDH mutations to
histone or DNA methylations in gliomas. Nonetheless, these
observations regarding changes in activities of epigenetic enzymes
by an oncometabolite, 2-HG continues to support direct connec-
tions between metabolic reprograming and epigenetic alterations
in cancers.
CONCLUSION
While we are still attempting to dissect out all of the various
epigenetic mechanisms and cellular metabolic changes in can-
cer, it is important to understand that many of these changes
and effects do not work in isolation. As discussed in this review,
we are in the process of discovering the previously unappreci-
ated link between cellular metabolism and epigenetic changes in
cancer development, and we expect that many more exciting dis-
coveries regarding these two interactions will come out in the
near future. One of the challenges will be to decipher what degree
and which precise regions of cancer epigenome are affected by
availability of specific metabolites in each stage of cancer develop-
ment and how altered metabolic flux and substrate competition
affect the dynamics of specific epigenetic modifications. For ther-
apeutic perspectives, it would be important to determine whether
these epigenetic changes elicited by altered metabolites can be
reversed by epigenetic therapy and whether any of the described
metabolic changes have prognostic or predictive value in cancer
patients. Epigenetic therapy has shown remarkable clinical activ-
ity for the treatment of various cancers (Dawson and Kouzarides,
2012). However, the biomarkers that could ultimately lead to
improved patient selection and diagnosis are poorly defined. One
possibility is that metabolic state of the tumor which could be
assessable from primary tumor biopsies or the metabolomics of
biological fluids could be used to predict the efficacy of targeted
epigenetic therapies (Locasale et al., 2012). If possible, the suc-
cessful application of metabolic biomarkers to predict response to
epigenetic therapy would provide strong evidence for the role of
metabolism in regulating epigenetics in tumors. Such biomarkers
would then expand on the potential of epigenetic therapy for ther-
apeutic gain. Although difficult, tackling these challenges will be
of increasing importance as the research evolves from the under-
standing of these interactions into the investigation of therapeutic
possibilities in cancer treatment.
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